New hope for elderly lung cancer: One-Drug immunotherapy trial launches
NCT ID NCT07596121
First seen May 22, 2026 · Last updated Jun 22, 2026 · Updated 6 times
Summary
This study tests whether the immunotherapy drug serplulimab alone can control advanced non-small cell lung cancer in patients aged 65 and older whose tumors have high PD-L1 levels. About 60 participants will receive the drug every three weeks until their disease worsens. The goal is to see how long the cancer stays under control and how safe the treatment is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital Affiliated to the Fourth Military Medical University
RECRUITINGXi'an, Shannxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Serplulimab (an immunotherapy drug given by IV every 3 weeks)
What this could lead to
If it works, this could offer a simpler, single-drug treatment option for elderly lung cancer patients with high PD-L1 levels.
What could go wrong
This is an early, small Phase II trial with only 60 patients, so results may not apply widely. Immunotherapy can cause side effects like inflammation of the lungs or other organs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.